Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Mené sur 303 patients atteints d'un cancer du poumon non à petites cellules ALK+, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, du taux de réponse objective et de la durée avant développement et/ou progression de métastases cérébrales, de l'alectinib et du crizotinib en traitement de première ligne
Background : The phase III ALEX study in patients with treatment-naïve advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer (NSCLC), met its primary endpoint of improved progression-free survival (PFS) with alectinib versus crizotinib. Here we present detailed central nervous system (CNS) efficacy data from ALEX. Patients and methods : Overall, 303 patients aged ≥18 years underwent 1:1 randomization to receive twice-daily doses of alectinib 600 mg or crizotinib 250 mg. Brain imaging was conducted in all patients at baseline and every subsequent 8 weeks. Endpoints (analyzed by subgroup: patients with/without baseline CNS metastases; patients with/without prior radiotherapy) included: PFS, CNS objective response rate (ORR), and time to CNS progression. Results : In total, 122 patients had Independent Review Committee-assessed baseline CNS metastases (alectinib, n = 64; crizotinib, n = 58); 43 had measurable lesions (alectinib, n = 21; crizotinib, n = 22), and 46 had received prior radiotherapy (alectinib, n = 25; crizotinib, n = 21). Investigator-assessed PFS with alectinib was consistent between patients with baseline CNS metastases [hazard ratio (HR) 0.40, 95% confidence interval (CI): 0.25–0.64] and those without (HR 0.51, 95% CI: 0.33–0.80, P interaction = 0.36). Similar results were seen in patients regardless of prior radiotherapy. Time to CNS progression was significantly longer with alectinib versus crizotinib and comparable between patients with and without baseline CNS metastases (P < 0.0001). CNS ORR was 85.7% with alectinib versus 71.4% with crizotinib in patients who received prior radiotherapy, and 78.6% versus 40.0%, respectively, in those who had not. Conclusion : Alectinib demonstrated superior CNS activity and significantly delayed CNS progression versus crizotinib in patients with previously untreated, advanced ALK+ NSCLC, irrespective of prior CNS disease or radiotherapy
Annals of Oncology 2018